ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 109 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.92 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,739,414 | -25.5% | 136,561 | +4.8% | 0.00% | 0.0% |
| Q2 2023 | $3,675,198 | +733.6% | 130,280 | +408.3% | 0.00% | – |
| Q1 2023 | $440,888 | -12.6% | 25,633 | +2.3% | 0.00% | – |
| Q4 2022 | $504,668 | -13.9% | 25,058 | -7.2% | 0.00% | – |
| Q3 2022 | $586,000 | -11.7% | 27,016 | +14.4% | 0.00% | – |
| Q2 2022 | $664,000 | -85.2% | 23,625 | -75.8% | 0.00% | -100.0% |
| Q1 2022 | $4,497,000 | -75.6% | 97,455 | -55.5% | 0.00% | -75.0% |
| Q4 2021 | $18,419,000 | +111.3% | 219,115 | +67.5% | 0.00% | +100.0% |
| Q3 2021 | $8,718,000 | +12.8% | 130,812 | -9.9% | 0.00% | 0.0% |
| Q2 2021 | $7,728,000 | -23.6% | 145,249 | -37.7% | 0.00% | -33.3% |
| Q1 2021 | $10,110,000 | -29.5% | 233,007 | -15.6% | 0.00% | -25.0% |
| Q4 2020 | $14,339,000 | +60.6% | 276,069 | +1.1% | 0.00% | +33.3% |
| Q3 2020 | $8,928,000 | -33.0% | 273,109 | -1.5% | 0.00% | -40.0% |
| Q2 2020 | $13,320,000 | – | 277,393 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,426,095 | $111,940,000 | 6.63% |
| Paradigm Biocapital Advisors LP | 287,577 | $13,269,000 | 3.51% |
| Avidity Partners Management LP | 3,176,999 | $146,587,000 | 3.05% |
| Integral Health Asset Management, LLC | 215,000 | $9,920,000 | 2.58% |
| Matrix Capital Management Company, LP | 4,349,279 | $200,676,000 | 2.41% |
| Affinity Asset Advisors, LLC | 207,500 | $9,574,000 | 1.53% |
| Ikarian Capital, LLC | 202,203 | $9,329,000 | 1.23% |
| Ghost Tree Capital, LLC | 80,000 | $3,691,000 | 0.80% |
| Eventide Asset Management | 761,000 | $35,113,000 | 0.55% |
| Perceptive Advisors | 501,509 | $23,140,000 | 0.46% |